Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

1.

Survival with first-line bosentan in patients with primary pulmonary hypertension.

McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, Rainisio M, Simonneau G, Rubin LJ.

Eur Respir J. 2005 Feb;25(2):244-9. Erratum in: Eur Respir J. 2005 May;25(5):942.

PMID:
15684287
[PubMed - indexed for MEDLINE]
Free Article
2.

Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.

McLaughlin VV.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:10-5.

PMID:
16919005
[PubMed - indexed for MEDLINE]
3.

Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

Denton CP, Humbert M, Rubin L, Black CM.

Ann Rheum Dis. 2006 Oct;65(10):1336-40. Epub 2006 Jun 22.

PMID:
16793845
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.

Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M.

Rheumatology (Oxford). 2010 Mar;49(3):490-500. doi: 10.1093/rheumatology/kep398. Epub 2009 Dec 16.

PMID:
20015974
[PubMed - indexed for MEDLINE]
Free Article
5.

Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.

Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ; Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group.

J Am Coll Cardiol. 2008 Dec 16;52(25):2127-34. doi: 10.1016/j.jacc.2008.08.059.

PMID:
19095129
[PubMed - indexed for MEDLINE]
Free Article
6.

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.

Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galiè N, Humbert M, Rainisio M, Rubin LJ, Simonneau G.

Thorax. 2005 Dec;60(12):1025-30. Epub 2005 Jul 29.

PMID:
16055621
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Bosentan therapy for pulmonary arterial hypertension.

Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G.

N Engl J Med. 2002 Mar 21;346(12):896-903. Erratum in: N Engl J Med 2002 Apr 18;346(16):1258.

PMID:
11907289
[PubMed - indexed for MEDLINE]
Free Article
8.

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.

Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ.

Lancet. 2001 Oct 6;358(9288):1119-23.

PMID:
11597664
[PubMed - indexed for MEDLINE]
9.

Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.

Jacobs W, Boonstra A, Brand M, Rosenberg DM, Schaaf B, Postmus PE, Vonk Noordegraaf A.

J Heart Lung Transplant. 2010 Oct;29(10):1150-8. doi: 10.1016/j.healun.2010.05.011. Epub 2010 Jun 26.

PMID:
20580264
[PubMed - indexed for MEDLINE]
10.

Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.

Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N; STRIDE-2 Study Group.

J Am Coll Cardiol. 2006 May 16;47(10):2049-56. Epub 2006 Apr 24.

PMID:
16697324
[PubMed - indexed for MEDLINE]
Free Article
11.

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study.

Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, Tapson VF, Rubin LJ.

Chest. 2003 Jul;124(1):247-54.

PMID:
12853530
[PubMed - indexed for MEDLINE]
12.

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.

Galiè N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G.

Lancet. 2008 Jun 21;371(9630):2093-100. doi: 10.1016/S0140-6736(08)60919-8.

PMID:
18572079
[PubMed - indexed for MEDLINE]
13.

Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.

Seyfarth HJ, Pankau H, Hammerschmidt S, Schauer J, Wirtz H, Winkler J.

Chest. 2005 Aug;128(2):709-13.

PMID:
16100158
[PubMed - indexed for MEDLINE]
14.

Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.

Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM.

J Heart Lung Transplant. 2005 Oct;24(10):1626-31.

PMID:
16210140
[PubMed - indexed for MEDLINE]
15.

Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension.

Degano B, Yaïci A, Le Pavec J, Savale L, Jaïs X, Camara B, Humbert M, Simonneau G, Sitbon O.

Eur Respir J. 2009 Jan;33(1):92-8. doi: 10.1183/09031936.00094808. Epub 2008 Sep 17.

PMID:
18799506
[PubMed - indexed for MEDLINE]
Free Article
16.
17.

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G.

Eur Respir J. 2004 Sep;24(3):353-9.

PMID:
15358690
[PubMed - indexed for MEDLINE]
Free Article
18.

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.

Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators.

Circulation. 2006 Jul 4;114(1):48-54. Epub 2006 Jun 26.

PMID:
16801459
[PubMed - indexed for MEDLINE]
Free Article
19.

Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G.

Eur Heart J. 2006 Mar;27(5):589-95. Epub 2006 Jan 23.

PMID:
16431875
[PubMed - indexed for MEDLINE]
Free Article
20.

Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation.

Hefke T, Zittermann A, Fuchs U, Schulte-Eistrup S, Gummert JF, Schulz U.

Thorac Cardiovasc Surg. 2012 Feb;60(1):26-34. doi: 10.1055/s-0030-1250726. Epub 2011 Mar 22.

PMID:
21432755
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk